PSParthipan Sivakumar

Parthipan Sivakumar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Parthipan Sivakumar has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The impact of outpatientversusinpatient management on health-related quality of life outcomes for patients with malignant pleural effusion: the OPTIMUM randomised clinical trial

    by Parthipan Sivakumar, Deirdre B. Fitzgerald, Hugh Ip, Deepak Rao, Alex West, Farinaz Noorzad, Deirdre Wallace, Mohamed Haris, Benjamin Prudon, Gihan Hettiarachchi, et al.

    Background The principal aim of malignant pleural effusion (MPE) management is to improve health related quality of life (HRQoL) and symptoms. Methods In this open-label randomised controlled trial, patients with symptomatic MPE were randomly assigned to either IPC insertion with the option of talc pleurodesis or chest drain and talc pleurodesis. The primary endpoint was global health status, measured with the EORTC QLQ-C30 questionnaire at 30 days post-intervention. 142 participants were enrolled from July 2015 to December 2019. Results Of participants randomly assigned to IPC (n=70) and chest drain (n=72), primary outcome data were available in 58 and 56 patients, respectively. Global health status improved in both groups at day 30 compared to baseline: IPC (mean difference 13.11 p=0.001) and chest drain (mean difference 10.11 p=0.001). However, there was no significant between-group difference at day 30 (mean inter-group difference in baseline-adjusted global health status of 2.06 ([95% CI −5.86 to 9.99]; p=0.61), day 60 or day 90. No significant differences were identified between groups in breathlessness and chest pain scores. All chest drain arm patients were admitted (median length of stay 4 days); 7 in the IPC arm required intervention-related hospitalization. Conclusion While HRQoL significantly improved in both groups, there were no differences in patient reported global health status at 30 days. The outpatient pathway using an IPC was not superior to inpatient treatment with a chest drain. Trial Registration: ISRCTN registration:15503522.


  • Open Access

    Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion

    by Deirdre B. Fitzgerald, Calvin Sidhu, Charley Budgeon, Ai Ling Tan, Catherine A. Read, Benjamin C. H. Kwan, Nicola Ann Smith, Edward T. Fysh, Sanjeevan Muruganandan, Tajalli Saghaie, et al.

    Introduction: Malignant pleural effusions (MPEs) are common. MPE causes significant breathlessness and impairs quality of life. Indwelling pleural catheters (IPC) allow ambulatory drainage and reduce hospital days and re-intervention rates when compared to standard talc slurry pleurodesis. Daily drainage accelerates pleurodesis, and talc instillation via the IPC has been proven feasible and safe. Surgical pleurodesis via video-assisted thoracoscopic surgery (VATS) is considered a one-off intervention for MPE and is often recommended to patients who are fit for surgery. The AMPLE-3 trial is the first randomised trial to compare IPC (±talc pleurodesis) and VATS pleurodesis in those who are fit for surgery. Methods and analysis: A multi-centre, open-labelled randomised trial of patients with symptomatic MPE, expected survival of ≥ 6 months and good performance status randomised 1:1 to either IPC or VATS pleurodesis. Participant randomisation will be minimised for (i) cancer type (mesothelioma vs non-mesothelioma); (ii) previous pleurodesis (vs not); and (iii) trapped lung, if known (vs not). Primary outcome is the need for further ipsilateral pleural interventions over 12 months or until death, if sooner. Secondary outcomes include days in hospital, quality of life (QoL) measures, physical activity levels, safety profile, health economics, adverse events, and survival. The trial will recruit 158 participants who will be followed up for 12 months. Ethics and dissemination: Sir Charles Gairdner and Osborne Park Health Care Group (HREC) has approved the study (reference: RGS356). Results will be published in peer-reviewed journals and presented at scientific meetings. Discussion: Both IPC and VATS are commonly used procedures for MPE. The AMPLE-3 trial will provide data to help define the merits and shortcomings of these procedures and inform future clinical care algorithms. Trial registration: Australia New Zealand Clinical Trial Registry ACTRN12618001013257. Registered on 18 June 2018. Protocol version: Version 3.00/4.02.19


  • Open Access

    P198 Outcomes of autologous blood pleurodesis in persistent air leak: An eight-year retrospective study

    by K Ur Rehman, L Okiror, P Sivakumar

    Introduction and Objectives Autologous blood pleurodesis (ABP) is one of the treatment options for recurrent pneumothorax and postoperative persistent air leak (PAL) following lobectomy. We aimed to assess the effectiveness of ABP in PAL. Methods Patients who underwent ABP from January 2013 to June 2021 were identified retrospectively through the procedure coding database and review of the pleural booking diary. Data was collected on demographics and treatment outcomes. Success was defined as cessation of PAL permitting drain removal within seven days of ABP. Results 68 patients underwent ABP averaging 8.5 patients per year. Mean age was 63 (SD 17.23). 18/68 (26.5%) patients were females. Results are summarised in table 1. Results Conclusion In this selected population, ABP is effective in the management of both surgical and medical PAL. Our data suggests high success rate not only as a first line therapy for PAL but also in cases where talc pleurodesis or endobronchial valve placement has failed.

  • Open Access

    Using creative co-design to develop a decision support tool for people with malignant pleural effusion

    by Cheryl Grindell, Angela Tod, Remi Bec, Daniel Wolstenholme, Rahul Bhatnagar, Parthipan Sivakumar, Anna Morley, Jayne Holme, Judith Lyons, Maryam Ahmed, et al.

    Background: Malignant pleural effusion (MPE) is a common, serious problem predominantly seen in metastatic lung and breast cancer and malignant pleural mesothelioma. Recurrence of malignant pleural effusion is common, and symptoms significantly impair people’s daily lives. Numerous treatment options exist, yet choosing the most suitable depends on many factors and making decisions can be challenging in pressured, time-sensitive clinical environments. Clinicians identified a need to develop a decision support tool. This paper reports the process of co-producing an initial prototype tool. Methods: Creative co-design methods were used. Three pleural teams from three disparate clinical sites in the UK were involved. To overcome the geographical distance between sites and the ill-health of service users, novel distributed methods of creative co-design were used. Local workshops were designed and structured, including video clips of activities. These were run on each site with clinicians, patients and carers. A joint national workshop was then conducted with representatives from all stakeholder groups to consider the findings and outputs from local meetings. The design team worked with participants to develop outputs, including patient timelines and personas. These were used as the basis to develop and test prototype ideas. Results: Key messages from the workshops informed prototype development. These messages were as follows. Understanding and managing the pleural effusion was the priority for patients, not their overall cancer journey. Preferred methods for receiving information were varied but visual and graphic approaches were favoured. The main influences on people’s decisions about their MPE treatment were personal aspects of their lives, for example, how active they are, what support they have at home. The findings informed the development of a first prototype/service visualisation (a video representing a web-based support tool) to help people identify personal priorities and to guide shared treatment decisions. Conclusion: The creative design methods and distributed model used in this project overcame many of the barriers to traditional co-production methods such as power, language and time. They allowed specialist pleural teams and service users to work together to create a patient-facing decision support tool owned by those who will use it and ready for implementation and evaluation.


  • Open Access

    Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial.

    by Rob J Hallifax, Edward McKeown, Parthipan Sivakumar, Ian Fairbairn, Christy Peter, Andrew Leitch, Matthew Knight, Andrew Stanton, Asim Ijaz, Stefan Marciniak, et al.


  • Open Access

    Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial

    by Rob J Hallifax, Edward McKeown, Parthipan Sivakumar, Ian Fairbairn, Christy Peter, Andrew Leitch, Matthew Knight, Andrew Stanton, Asim Ijaz, Stefan Marciniak, et al.


  • Open Access

    Coexistent COVID-19 pneumonia and pulmonary embolism: challenges in identifying dual pathology

    by Katrina Abernethy, Parthipan Sivakumar, Tanya Patrick, Hasti Robbie, Jimstan Periselneris


  • Open Access

    Multidisciplinary approach to connective tissue disease (CTD) related pleural effusions: a four-year retrospective evaluation

    by Hugh Ip, Parthipan Sivakumar, Eugene Ace McDermott, Sangita Agarwal, Boris Lams, Alex West, Liju Ahmed

    CTD-related pleural effusions are rare and challenging to diagnose. Our lung inflammation service (with expertise in rheumatology, interstitial lung disease and respiratory failure) works closely with the pleural team. This study aims to review the multidisciplinary approach to CTD-related pleural effusions at a tertiary centre. All patients with CTD-related pleural effusions at St Thomas’ Hospital, London were included. Retrospective data were collected from Dec 2013 to 2016. The lung inflammation service performed an expert clinical assessment and targeted investigations. 11 patients (ages 23–77) were identified with CTD related pleural disease. 9 (82%) patients were given a new CTD diagnosis, with pleural disease as the first manifestation. The range of conditions were: rheumatoid arthritis [3] ,IgG4-related disease [2] ,adult Still’s disease [2] ,vasculitis [1] ,SLE [1] ,drug-induced lupus [1] ,and Behcet’s [1]. The pleural team review took place 1 day (median) after referral. 73% of diagnoses (8 patients) were achieved with local anaesthetic pleural interventions (a combination of: aspiration, drain, or percutaneous biopsy). This included 1 patient who required no pleural intervention. 1 required medical thoracoscopy, and 2 underwent thoracic surgery. Diagnoses were made by integrating all available evidence such as clinical assessment, imaging, and autoimmune serology. No diagnosis was achieved by pleural cytology or histology analysis alone. 8 (73%) were commenced on prednisolone acutely (vasculitis, SLE, drug-related lupus, 1 patient with rheumatoid arthritis, Behcet’s, 2 patients with Adult Still’s disease, 1 patient with IgG4-related disease). Of these 8, one patient with rheumatoid arthritis received IV methylprednisolone beforehand, one patient with IgG4-related disease was weaned off prednisolone to methothrexate, two patients with Adult Still’s disease were on colchicine as well, and one patient with Behcet’s was on cyclophosphamide as well. 7 (64%) were managed as outpatients; 4 required admission. The median time from pleural review to diagnosis was 53 days. Diagnosis can be challenging in patients presenting with pleural disease as the first manifestation of a CTD. We recommend a multidisciplinary approach in management.


  • Quality of life after interventions for malignant pleural effusions: a systematic review

    by Parthipan Sivakumar, Anita Saigal, Liju Ahmed

    Background Malignant pleural effusion (MPE) results in breathlessness and impairment of health-related quality of life (HRQOL). This study reviews the existing literature on HRQOL following invasive interventions in MPE. Methods Five electronic databases were systematically searched and assessed three times during the review process and last completed on 15 June 2018. We included all studies evaluating HRQOL outcomes for the following interventions: therapeutic thoracocentesis, talc slurry (TS) pleurodesis, indwelling pleural catheter (IPC) insertion and thoracoscopic talc poudrage (TTP) pleurodesis. Meta-analysis was not performed due to substantial heterogeneity in the published data. Results 17 studies were included in the review reporting HRQOL outcomes in 2515 patients. TTP, TS and IPC were associated with modest but inconsistent improvements in HRQOL up to 12 weeks. No intervention was significantly different from another in HRQOL outcomes at any time point. The attrition to follow-up was 48.3% (664/1374) at 3 months. The overall quality of studies was inadequate. Conclusion TTP, TS and IPC seem to improve HRQOL in MPE over 4–12 weeks, but there are insufficient longer term data due to high attrition rates. Evidence on the most effective treatment strategy is limited by the small number of randomised or comparative studies. Trial registration number CRD42016051003.


  • Multidisciplinary approach to connective tissue disease (CTD) related pleural effusions

    by Hugh Ip, Parthipan Sivakumar, Eugene Ace Mcdermott, Sangita Agarwal, Boris Lams, Alex West, Liju Ahmed

    Introduction: CTD-related pleural effusions are challenging to diagnose. Our lung inflammation service (rheumatology, ILD, respiratory failure) works closely with the pleural team (consultants, specialist nurses, clinical/research fellows). Aims and objectives: To review the multidisciplinary approach to CTD-related pleural effusions at a tertiary centre. Methods: All patients with CTD-related pleural effusions at St Thomas’ Hospital, London were included. Retrospective data were collected from Dec 2013 to 2016. Results: The lung inflammation service performed an expert clinical assessment and targeted investigations. 11 patients (ages 23-77) were identified with CTD-related pleural disease. 9 (82%) patients were given a new CTD diagnosis, with pleural disease as the first manifestation. The range of conditions were: rheumatoid arthritis (3), IgG4-related disease (2), adult Still’s disease (2), vasculitis (1), SLE (1), drug-induced lupus (1), and Behcet’s (1). The pleural team review took place 1 day (median) after referral. 73% of diagnoses (8 patients) were achieved with local anaesthetic pleural interventions (a combination of: aspiration, drain, or percutaneous biopsy). This included 1 patient who required no pleural intervention. 1 required medical thoracoscopy, and 2 underwent thoracic surgery. 7 (64%) were commenced on prednisolone acutely, of whom 1 received IV methylprednisolone beforehand. 7 (64%) were managed as outpatients; 4 required admission. The median time from pleural review to diagnosis was 53 days. Conclusions: Diagnosis can be challenging in patients presenting with pleural disease as the first manifestation of a CTD. We recommend a multidisciplinary approach in management.